Adverse events during anti-TNF therapy in 269 patients with juvenile idiopathic arthritis

Table 1 AEs and SAEs per patient-year during anti-TNF therapy

	etanercept	infliximab	adalimumab	all
AEs	1,40	1,51	2,34	1,48
SAEs	0,09	0,06	0,08	0,07
All infections	0,79	0,74	0,66	0,77
upper respiratory	0,47	0,40	0,33	0,44
serious infections	0,04	0,02	0,04	0,03
hypersensitivity reactions	0,03	0,23	0,29	0,12

ISSN: 1546-0096